This article from Forbes reports on a new venture capital fund started by three former executives of Millennium Pharmaceuticals: Mark Levin, Kevin Starr, and Bob Tepper. They just raised $378 million for what they're calling Third Rock Ventures. According to the article, the fund will be closely managing startup companies, and will "only look at a few biotechs, each getting a few tens of millions of dollars."

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.